Bausch Health Companies

Bausch Health, through its aesthetics division Solta Medical, is introducing the Fraxel FTX laser system in Australia. The upgraded system uses two wavelengths (1927 nm for the epidermis, 1550 nm for the dermis), creates microscopic treatment zones and targets indications such as fine lines, wrinkles, acne scars, pigment lesions, as well as actinic keratosis and melasma. Innovations include a lighter handpiece, integrated cooling, AccuTRAC tracking and a modernized user interface; the device is prescription-only and will be supported by Solta Medical with clinical and hands-on training. » More on de.investing.com

Bausch Health shares closed at $4.56, marking a 52-week low and a one-year performance of -28.42%. Analysts nevertheless see upside and cite price targets between $6 and $9, while data from InvestingPro classify the stock as undervalued. Investors are watching the quarterly report due in eight days, seen as a potential turning point for the $1.75 billion pharmaceutical group. » More on de.investing.com

Bausch Health Canada secured listing of PrOKEDI 75mg and 100mg dosages in the Régie de l'assurance maladie du Québec formulary, marking a key reimbursement milestone for the injectable risperidone treatment for adults with schizophrenia. PrOKEDI provides rapid therapeutic concentrations without oral supplementation or a loading dose and offers four-week dosing. The company said it will pursue coverage in other provinces following a prior Letter of Intent from the pan-Canadian Pharmaceutical Alliance to advance public drug program access. » More on finance.yahoo.com